Business
OraSure Director Nancy Gagliano Selected to Serve as Interim Chief Executive Officer; Brings Extensive Diagnostics and Healthcare Leadership Experience to Role
Board Continues Search for Permanent CEO Evaluation of Strategic Alternatives Ongoing BETHLEHEM, Pa., March 22, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies,
About this update from Orasure Technologies, Inc.
[{"type":"text","content":"Board Continues Search for Permanent CEO Evaluation of Strategic Alternatives Ongoing BETHLEHEM, Pa., March 22, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, today announced that its Board of Directors (the “Board”) has appointed Nancy Gagliano, MD to serve as interim Chief Executive Officer, effective April 1, 2022. Dr. Gagliano is not a candidate for the permanent CEO position. As previously announced, Stephen Tang Ph.D., President and CEO, will be the leaving the Company as of March 31, 2022. The Board’s search for a permanent CEO is actively underway. Dr. Gagliano, a member of the OraSure Board since November 2021, brings extensive leadership experience in the diagnostics and healthcare industries to this role, including recent service as an executive leader of the National Institute of Health’s RADx Tech, a program focused on speeding the development, validation, and commercialization of innovative point-of-care and over-the-counter tests that can directly detect the COVID-19 virus. Dr. Gagliano, previously a practicing physician, has also held senior leadership positions at CVS Health, including as Chief Medical Officer of Minute Clinic. “With decades of leadership in the diagnostics and healthcare industries, including helping to oversee the government’s widescale efforts to accelerate the development and commercialization of diagnostic tests for COVID-19, Nancy is well-suited to serve as interim CEO at OraSure,” said OraSure Chairman of the Board Michael Celano. “As she has demonstrated since joining the OraSure Board, Nancy is an engaged and thoughtful leader. In her new role, she will work closely to support Lisa Nibauer, President of Diagnostics, and Kathleen Weber, President of Molecular Solutions, and other members of the leadership team as we continue to focus on scaling the business and driving profitable growth.” He continued, “The Board and senior leadership team continue to evaluate available strategic alternatives to maximize stockholder value and prepare for an orderly transition to a new CEO. We appreciate Steve’s contributions and wish him well in his future activities.” On January 5, 2022, the Company announced its intent to explore and evaluate a broad ...